Numerous organometallic (η 6 -arene)-ruthenium complexes have been screened as anticancer agents with promising results, for instance, compounds of the types [(η 6 -arene)Ru(NN)Cl] + (NN = chelating nitrogen ligands, especially ethylenediamine (en)), [1] [2] [3] [(η 6 -arene)Ru(NO)Cl] (NO = 3′-fluorophenyl-3-(phenylamino)-2-buten-1-one), 4 [(η 6 -arene)Ru(OO)X] (OO = 3-hydroxyflavone derivatives, X = Cl, Br or I) 5, 6 [11] [12] [13] However, none of these Cp/Cp* ruthenium complexes has been tested under hypoxic conditions. Some diphosphines have demonstrated cytotoxicity against various cell lines, 14 but it has been observed that, upon coordination to metals, diphosphines produce complexes with improved anticancer activity compared to the free ligands; a general hypothesis considers that the metal protects the ligands from oxidation before they interact with the corresponding biological target. . We investigated the biological activity of both ligands and the effect of complexation. We were interested in assessing the impact of hydrophilic functionalisation of Cp* with an -OH group and the different cytotoxicities shown by analogous neutral and charged complexes. The anticancer activities were assessed against A2780 and HT-29 cell lines, for HT-29 both at 21% and 0. 6 ] complexes, where PP = chiral diphosphines. 22 The structure of complex 3 was determined by single crystal X-ray diffraction. Compound 3 crystallised in a triclinic cell from pentane/chloroform, and the structural solution was performed in the space group P ̅ . The asymmetric unit comprises one molecule of compound 3, including the counterion SbF 6 . The molecular structure of 3 is shown in Figure  1 and selected bond lengths and angles are given in Table 1 . Compound 3 presents the characteristic piano-stool geometry typical of η 5 -and η 6 -organometallic ruthenium species. The N(1)-C(11) triple bond length is 1.153(2) Å. The cytotoxic activities of compounds 1-5, along with cisplatin, dppm and Xantphos were tested on the A2780 and HT-29 cell lines after five-day exposures at 37 ºC and 21% O 2 . The IC 50 results are shown in Table 2 . The most active complexes were those formed from dppm, 1, 2 and 3, all with better cytotoxicities, in the nanomolar range, than cisplatin for both HT-29 and A2780 cell lines. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012
Dppm was active by itself, with IC 50 values below 1.5 µM. However, 1 H and 31 P NMR spectroscopy experiments in deuterated DMSO showed no de-coordination of dppm from complexes 1 and 3 after five days. The observation that diphosphines do not dissociate is further reinforced by the fact that complexes 4 and 5 gave moderate to good activities, which are not due to a possible release of the ligand, because Xantphos did not show anticancer behaviour on its own. This contradicts the previous hypothesis that the activities of these types of diphosphine complexes depend on possible de-coordinations of the ligands. 15 The extremely different behavior of dppm and Xantphos provides interesting material for further future studies. Complexes 4 and 5 were more active against A2780 cells, with IC 50 values close to cisplatin. The presence of the (CH 2 ) 5 OH chain in the Cp # compounds 2 and 5 produced no great effect on their anticancer activities, compared to those of the Cp* complexes 1 and 4. The best cytotoxicity was observed for the positively charged complex 3. To assess the extent of hydrolysis 23 in complexes 1 and 3, 10 mM samples of both complexes in 0.6 ml of deuterated solvent (90% deuterated DMSO + 10% deuterium oxide) were prepared in NMR tubes and analysed by 1 H NMR spectroscopy every 24 hours during five days at room temperature. A new set of peaks at 5.14 and 1.61 ppm appeared gradually in both samples (see Fig. S1 in the ESI) . The new species formed, after five days, in 48% yield from complex 1 and in 67% yield from complex 3. Mass spectrometry of this new species showed the same peaks observed for the chloride complex 1, where the chloride ligand was lost. By inference, the new species is believed to be the aqua species, which entails that monocationic complex 3 hydrolyses to a higher extent under the same conditions, and this coincides with its higher anticancer activity. Table 2 gives the IC 50 results obtained for the most active compounds 1-3 against hypoxic HT-29 cells at an oxygen concentration of 0.1%. Cancerous cells are known to proliferate within hypoxic environments, with oxygen content below 2%, 24 therefore hypoxic experiments tend to reproduce the conditions found in human solid tumours. Apart from cisplatin, whose activity remains practically unmodified, tirapazamine, a drug known to be hypoxia sensitive, 25 was also employed as reference. Interestingly, the IC 50 of dppm under hypoxic conditions increased considerably from 1.47 µM to 17.19 µM. A possible explanation for this is that the active species might be an oxidized form of dppm. However, Samuelson et al. have reported that, while dppm is moderately active against H460 lung cells (IC 50 = 18.2 μM), mono-oxidised dppm shows no cytotoxic activity (IC 50 > 250 μM), 9 and similar conclusions had been drawn by Sadler et al. 14 The activities of complexes 1-3 improved slightly at a low O 2 concentration. Complex 3 showed again the best performance, with an IC 50 of 0.55 ± 0.03 µM, and is of particular significance and interest. 
